VIEW FROM HERE:  Sovaldi Redux—The States Muddle Through

By Christopher F. Koller
President of the Milbank Memorial Fund

What kind of coverage decisions are states making about Sovaldi, the new Hepatitis C drug that costs $1,000 a pill or up to $168,000 a treatment? The drug presents new hope for patients, but grave risks to Medicaid and state corrections budgets, both of which must pay for care for a disproportionate number of people with Hepatitis C. 

READ MORE


NEW IMPACT FACTOR SCORE

The 2013 Institute for Scientific Information (ISI) Impact Factors were recently readjusted—and The Milbank Quarterly now has an impact factor of 5.391. The ISI impact factor is the gold standard...

READ MORE


TRANFORMING PRIMARY CARE REPORT

A new Milbank Memorial Fund report, “Aligning Payers and Practices to Transform Primary Care: A Report from the Multi-State Collaborative,” describes the efforts in states to take on the challenges of primary care transformation and payment reform. 

READ MORE

 

NEW: From Howard Markel, Editor-in-Chief of The Milbank Quarterly: What A Past Epidemic Teaches Us About Ebola

Milbank Quarterly study, "Return on Investment: A Fuller Assessment of the Benefits and Cost Savings of the US Publicly Funded Family Planning Program," in the Washington Post

From Howard Markel, Editor-in-Chief of The Milbank Quarterly: Before Ebola, Ellis Island's Terrifying Medical Inspections

Howard Markel, Editor-in-Chief of The Milbank Quarterly: PBS NewsHour Interview

READ MORE

The Milbank Memorial Fund is an endowed operating foundation that works to improve the health of populations by connecting leaders and decision makers with the best available evidence and experience. Founded in 1905, the Fund engages in nonpartisan analysis, collaboration, and communication on significant issues in health policy. It does this work in three ways:

  • Publications—We publish high quality, evidence-based reports, books, and The Milbank Quarterly, a peer-reviewed journal of population health and health policy.

  • Programs—We convene state health policy decision makers on issues they identify as important to population health and facilitate the development of policies that work for them and their constituents.

  • People—We build communities of health policymakers to enhance their effectiveness.

CURRENT ISSUE

September 2014 (Volume 92, Number 3)
Table of Contents

Current Featured Article

Revisiting Financial Conflicts of Interest in FDA Advisory Committees
Genevieve Pham-Kanter

GO TO QUARTERLY PAGE

LATEST REPORT

Health Worker Shortages and Global Justice   
Paula O'Brien and Lawrence O. Gostin
2011

 

GO TO REPORTS PAGE

RECENT BOOK

Lead Wars: The Politics of Science and the Fate of America's Children
Gerald Markowitz and David Rosner
2013


GO TO BOOKS PAGE